Literature DB >> 19783968

Molecular profile and cell cycle in MCF-7 and MCF-7/Dox cells exposed to conventional and liposomal forms of doxorubicin.

N V Rusetskaya1, N Yu Lukyanova, V F Chekhun.   

Abstract

AIM: To compare the molecular profile and cell cycle of sensitive and resistant to doxorubicin MCF-7 breast cancer cells upon exposition to conventional or liposome-encapsulated forms of doxorubicin.
METHODS: capital EM, Cyrilliccapital TE, Cyrilliccapital TE, Cyrillic-test, immunocytochemistry, flow cytometry.
RESULTS: In sensitive MCF-7 cells the exposure to conventional but not liposomal form of doxorubicin decreased metallothionein (MT) expression demonstrating activation of MT-detoxification system. In doxorubicin-resistant cells (MCF-7/Dsmall o, Cyrillicsmall ha, Cyrillic) MT expression drastically decreased. Conventional but not liposomal form of doxorubicin reduced the levels of expression of steroid hormones receptors on MCF-7 sensitive cells. The exposure of MCF-7 cells to conventional form of doxorubicin resulted in the decrease of p53 expression and the increase of Bcl-2 expression. In MCF-7/Dsmall o, Cyrillicsmall ha, Cyrillic cells neither conventional nor liposomal form of doxorubicin altered Bcl-2 expression. The exposure of MCF-7 but not MCF-7/Dsmall o, Cyrillicsmall ha, Cyrillic to doxorubicin in conventional form caused cell cycle arrest in G0/G1. Upon exposure to doxorubicin in liposomal form, cell cycle blockage in G0/G1 phase was observed in both sensitive and resistant sublines.
CONCLUSION: The differential effects of the conventional and liposomal forms of doxorubicin in sensitive and resistant cells have been demonstrated. Exposure of MCF-7 and MCF-7/Dsmall o, Cyrillicsmall ha, Cyrillic cells to doxorubicin in liposomal form alters the molecular profile and cell distribution over cell cycle phases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19783968

Source DB:  PubMed          Journal:  Exp Oncol        ISSN: 1812-9269


  6 in total

1.  Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells.

Authors:  El-Shaimaa A Arafa; Qianzheng Zhu; Zubair I Shah; Gulzar Wani; Bassant M Barakat; Ira Racoma; Mohamed A El-Mahdy; Altaf A Wani
Journal:  Mutat Res       Date:  2010-10-30       Impact factor: 2.433

2.  A mechanistic study of the effect of doxorubicin/adriamycin on the estrogen response in a breast cancer model.

Authors:  Jessica E Pritchard; Patrick M Dillon; Mark R Conaway; Corinne M Silva; Sarah J Parsons
Journal:  Oncology       Date:  2012-09-05       Impact factor: 2.935

3.  A critical dose of doxorubicin is required to alter the gene expression profiles in MCF-7 cells acquiring multidrug resistance.

Authors:  Shang-Hsun Tsou; Tzer-Ming Chen; Hui-Ting Hsiao; Yen-Hui Chen
Journal:  PLoS One       Date:  2015-01-30       Impact factor: 3.240

4.  Synergistic growth inhibitory effect of deracoxib with doxorubicin against a canine mammary tumor cell line, CMT-U27.

Authors:  Tülay Bakirel; Fulya Üstün Alkan; Oya Üstüner; Suzan Çinar; Funda Yildirim; Gaye Erten; Utku Bakirel
Journal:  J Vet Med Sci       Date:  2016-01-29       Impact factor: 1.267

5.  Exostosin 1 regulates cancer cell stemness in doxorubicin-resistant breast cancer cells.

Authors:  Sarala Manandhar; Chang-Gu Kim; Sun-Hee Lee; Soo Hyun Kang; Nikita Basnet; You Mie Lee
Journal:  Oncotarget       Date:  2017-07-31

6.  Cellular Mechanisms Triggered by the Cotreatment of Resveratrol and Doxorubicin in Breast Cancer: A Translational In Vitro-In Silico Model.

Authors:  José Eduardo Vargas; Renato Puga; Guido Lenz; Cristiano Trindade; Eduardo Filippi-Chiela
Journal:  Oxid Med Cell Longev       Date:  2020-11-01       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.